Syndax Files Registration Statement for Proposed Initial Public Offering
WALTHAM, Mass., March 27, 2014 /PRNewswire/ , Inc. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of shares of its common stock. All shares of common stock to be sold in the offering will be offered by Syndax. The number of shares to be offered and the price range for the offering have not yet been determined.
Deutsche Bank Securities and Jefferies are acting as joint book running managers for the offering. JMP Securities and Wedbush PacGrow Life Sciences are acting as co managers.
A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering will be made only by means of a prospectus. Entinostat is designed to prolong the effectiveness of current cancer treatments through an epigenetic mechanism and has been designated a Breakthrough Therapy by the FDA when used in combination with exemestane in estrogen receptor positive metastatic breast cancer.
Help employers find you! Check out all the .
Related News
Inc. Announces National Cancer Institute And FDA Reach Agreement On A Special Protocol Assessment (SPA) For The Phase 3 Trial Of Entinostat In Patients With Advanced ER+ Breast Cancer Agile Therapeutics, Inc. Files For $69 Million IPO
Recent Comments